職位推薦
- 珍格醫療-臨床銷售 15001-20000
- 地奧制藥-醫藥代表 6001-8000
- 普利德醫療-醫療設備銷售經理 面議
- 大唐-兼職招商經理 面議
- 景德中藥-直營經理 6001-8000
- 安邦醫藥-省區招商經理 8001-10000
- 恒瑞醫藥-醫藥信息溝通專員 6001-8000
- 黃河中藥-學術講師 8001-10000
發布日期:2017-05-12 瀏覽次數:54
中山大學腫瘤防治中心2017年
博士后招聘啟事
中山大學腫瘤防治中心(中山大學附屬腫瘤醫院、中山大學腫瘤研究所)成立于1964年3月,是新中國成立最早的四所腫瘤醫院之一。中心是全國規模最大、學術力量最雄厚的集醫療、教學、科研、預防于一體的腫瘤學基地之一,學科地位、綜合實力居全國領先水平。
現實際開放病床數1489張,設有32個業務科室,8個職能處室,2個研究科室。2016年門診量達83萬余人次,出院人數近9.4萬余人次,醫療業務量居全國腫瘤專科醫院前列。醫療技術水平領先,擁有軟硬件條件亞洲一流的放射治療中心、開展多個??剖中g機器人微創手術。
中心是國家重點學科(腫瘤學)、國家重點實驗室(華南腫瘤學國家重點實驗室)??萍加绊懥Ψ€居“中國醫院科技影響力排行榜”(腫瘤學)前兩位。共有75個項目獲得省部級以上科研成果獎勵,其中包括國家自然科學二等獎1項、國家科技進步二等獎4項等。主辦英文學術期刊 Chinese Journal of Cancer,2014年被SCI收錄,2015年影響因子2.814,在國內被收錄腫瘤學期刊中位列第一。
中心以優秀的文化引才、聚才,凝聚高水平的醫教研隊伍,現有員工2645人。中心通過優化管理體制,推進軟硬件建設,建成了就醫方便、流程合理、賓至如歸的花園式人文醫院;繼承“誠實、友愛、敬業、創新”的文化因子,2016年榮獲中國醫療機構最佳雇主排行榜冠軍。
中心擁有良好的科研平臺、完善的學科結構和雄厚的經費支持,可為博士后提供優厚的福利待遇和廣闊的發展空間。2017年面向海內外招聘博士后研究人員79位,歡迎有志于腫瘤防治研究事業的優秀博士畢業生加入!招聘事項如下:
一、招收條件:
1、取得博士學位,品學兼優,身心健康,具備較高的學術水平和較強的科研能力。
2、首次進站人員年齡一般在35歲以下,博士畢業不超過兩年。企業、基地博士后、留學回國人員、外籍人員、擬進二站人員、特別優秀的人員年齡可放寬到40歲以下,無博士畢業與博士后進站間隔年限限制。
3、科研博士后原則上不接受在職人員的申請。
4、在本校獲得博士學位的畢業生,不得申請進入校內相同一級學科的流動站。
二、福利待遇:
1、年薪20-25萬元(稅前)
2、繳納五險一金。
3、解決廣州市戶口。
4、在站期間業績優秀,可申請本中心專職科研人員職位;在站期間發表IF 10以上論文,可根據崗位需要,申請調入。
三、出站要求:在站期間發表IF 3.0以上SCI論文1篇以上,獲得科研基金1項以上。
四、招聘人數及期限:77名,常年招聘,額滿為止。
五、招聘程序
1、申請者選擇合作導師,與導師溝通,確定合作意向。導師信息及專業要求見附件,也可在中山大學【博士后之家】或本中心官網【名醫名家】查閱。
2、投遞簡歷。申請者可選擇以下三種方式投遞簡歷:(1)將簡歷發到合作導師郵箱;(2)將簡歷上傳到在本中心誠聘英才/博士后崗位;(3)將簡歷發到由本中心人事處老師郵箱,由人事處老師推薦合作導師。
3、進站面試。由本中心博士后管理小組專家對申請者進行面試(國外申請者可進行視頻面試)。申請者須做15-30分鐘學術報告,主要內容包括申請者的基本情況,以往研究工作經歷,今后的研究方向,以及與合作導師研究方向一致性等。
4、提交材料。申請者根據中山大學博士后之家/博士后進站材料一覽表要求,進入中國博士后網進行網上申報;準備好相關材料,提交本中心人事處老師審核。
5、上報審批。由本中心人事處對應聘者提交的材料進行初審,通過初審的材料再提交中山大學博士后管理辦公室審核,最后報廣東省人事廳審批。此過程約需一個月左右。
六、聯系方式
聯系人:楊老師 文老師
聯系地址:廣州市越秀區東風東路651號 中山大學腫瘤防治中心人事處
電話:020-87343130、87343129
QQ群(博雅齋):157357002
2017 SunYat-senUniversityCancerCenter
PostdoctoralPositions
Sun Yat-sen University Cancer Center (SYSUCC) was established in 1964 and is one of the four earliest tumor hospitals in China. SYSUCC is leading the way on a national frontier. It is the largest integrated cancer center in the whole of southern China for cancer care, education, research and prevention.
SYSUCC is a modern medical service provider equipped with 1489 ward beds, 32 clinical departments, 8 administrative offices and 2 research departments. In 2016, the center performed 830,000 out-patients consultations and 94,000 patients were hospitalized, providing the largest volume of cancer medical service in China. Equipped with state of the art medical technology, SYSUCC has a premier radiation therapy center and recently introduced the da Vinci robot for minimally invasive surgeries.
Sun Yat-sen University Cancer Center has been awarded many prestigious titles: the National Key Disciplines (Oncology), the State Key Laboratory (SKL) of Oncology in South China, etc. SYSUCC has always closely combined its clinical and research attributes, ranking top two in the Chinese Hospital of Scientific Impact Ranking.
Altogether,seventy-five projects have been awarded with scientific achievement awards of provincial level or above, including one project with the second prize of “National Natural Science Award”, four projects with the second prize of “National Science and Technology Progress Award”. SYSUCC houses the editorial office of the Chinese Journal of Cancer (CJC). In 2014, CJC became Science Citation Indexed (SCI), and its impact factor of 2015 reached 2.814, ranking first among the national journals of Oncology.
With over 2,500 staff members, Sun Yat-sen University Cancer Center has recruited a talented team for patient care, education and scientific research. Through infrastructure optimization, software and management system upgrades, SYSUCC has created an efficient working environment for its employees, as well as a patient-oriented atmosphere. In 2016, SYSUCC was ranked first in the Chinese Hospitals Best Employer Ranking.
With the establishment of high level research platforms, a mature discipline structure as well as strong funding support, SYSUCC is now offeringgenerous post-doctoral researcher benefits and promising career opportunities. In 2017, 79post-doctoral positions will be made availableat SYSUCC. Enthusiastic applicants with a recent PhDand related research background arestrongly encouraged to apply.Join us and investigate inthe fields of cancer treatment and prevention.
Eligibility Requirements:
1. Good general health, with a doctor’s degree, high academic achievements and strong research ability
2. For recent PhD graduates: you must be under the age of 35 and have completed your PhD degree within the last 2 years.
For Post-docs from industry, postdoctoral bases, abroad, foreign or outstanding applicants: must be under the age of 40.
3. To commit to a full-time employment position.
4. For SYSU PhD graduates only: you mustnot apply to the Postdoctoral Training Stationfor the same discipline.
Welfare and Benefits
1. Annual salary: 200,000 – 250,000 RMB (before tax)
2. Pay the basic social insurance and housing fund (for Chinese applicants)
3. Guangzhou hukou (for Chinese applicants)
4. Post-docs with excellent academic performance can apply for a researcher’s position in SYSUCC afterwards.
Requirement for Postdoctoral Training Completion
You must publish at least one SCI paper with an impact factor above 3.0and receive at least one research funding grant in order to gain the post-doc training certificate. Information and help about funding opportunities at that stage will be disclosed at a later date.
Total number of enrollment:77
Application procedure
1. Please communicate first with potential supervisors. Attached is the contact information and research specialty for each of the supervisors. You can also check SYSUCC official website or the following website: http://rsc.sysu.edu.cn/postdoctor/
2. Please submit your CV by: (1) sending it to your supervisor via email. (2) submit it online to our Chinese website(3)send it to our Human Resources Department, and we will then help to recommend you to suitable supervisors
3. Interview: experts from the Post-doc Administration Group are in charge of interviewing all applicants(international applicants can be interviewed via teleconferencing). A 15-30 minute academic presentation is required, including a general self-introduction, introduction of your former research experience as well as your future work plan.
4. Document submission: applicants should prepare all the materials as required (http://rsc.sysu.edu.cn/PostDoctor/Article/ShowArticle.asp?ArticleID=1088), and submit themto the following website: http://www.chinapostdoctor.org.cn/WebSite/program/Default.aspx Please prepare the related documents for review by our HR team.
5. Approval: After approval by our HR, documents will be submitted to the Office of Postdoctor Management at Sun Yat-sen University, and then to the Personnel Department of Guangdong Province for final approval. The whole procedure takes approximately 30 days.
Contact
Contact person: Mrs. Yang, Mrs. Wen
Address: Personnel Department, Sun Yat-sen University Cancer Center, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou, China
Tel: 86 20 87343130, 86 20 87343129
Email: yangping@sysucc.org.cn
QQ: 157357002
附:招收信息
序號 |
合作導師姓名Supervisor |
二級學科Second-level discipline |
研究方向Field of research |
招收人數 | |||
中文 |
英文 |
中文 |
英文 |
中文 |
英文 | ||
1 |
夏小俊 |
Xiaojun Xia |
分子醫學 |
Molecular Medicine |
天然免疫和腫瘤免疫治療 |
Innate immunity&Cancer immunotherapy |
2 |
2 |
劉學奎 |
XuekuiLiu |
頭頸腫瘤學/耳鼻喉科學 |
Head and neck /oncologyotolaryngology |
喉癌的基礎和臨床研究 |
Basic and clinical research of laryngeal cancer |
1 |
3 |
曾益新 |
Yi-Xin Zeng |
腫瘤學 |
Oncology |
惡性腫瘤的發病機理及腫瘤的生物治療 |
Mechanisms of cancer pathogenesis andbiotherapy |
2 |
4 |
黃必軍 |
Bi-Jun Huang |
腫瘤學 |
oncology |
腫瘤干細胞 |
Cancer stem cells |
1 |
5 |
林東昕 |
Dongxin Lin |
腫瘤學 |
Oncology |
腫瘤分子生物學 |
Molecular Oncology |
2 |
6 |
鄭健 |
Jian Zheng |
腫瘤學 |
Oncology |
腫瘤分子生物學 |
Molecular Oncology |
1 |
7 |
文石軍 |
Shijun Wen |
腫瘤學,藥物化學 |
Oncology, Medicinal Chemistry |
抗腫瘤藥物及有機合成方法學研究 |
Anticancer drug discovery and the development of organic synthetic methodology |
2 |
8 |
陳帥 |
Shuai Chen |
腫瘤學 |
Oncology |
免疫調節與癌變 |
Immune regulation and carcinogenesis |
2 |
9 |
唐海林 |
HailinTang |
腫瘤學 |
Oncology |
腫瘤學 或 分子醫學 |
Oncology or Molecular Medicine |
1 |
10 |
馬駿 |
Jun Ma |
腫瘤放射治療學 |
RadiotherapyofOncology |
鼻咽癌分子預后與多學科精準治療 |
Molecular prognosis and multidisciplinary precision therapy of nasopharyngeal carcinoma |
4 |
11 |
石明 |
Shi Ming |
腫瘤學 |
Oncology |
肝癌 |
hepatocellular carcinoma |
1 |
12 |
邵建永 |
JianyongShao |
腫瘤學 |
Oncology |
腫瘤高通量測序和數據挖掘 |
Tumor high-throughput sequencing and data mining |
1 |
13 |
李曉星 |
Xiaoxing Li |
腫瘤學 |
Oncology |
腫瘤分子生物學 |
Molecular Oncology |
1 |
14 |
鄭曉峰 |
腫瘤學 |
Oncology |
腫瘤分子生物學 |
Molecular Oncology |
3 | |
15 |
呂躍 |
Yue Lu |
腫瘤學 |
Oncology |
血液腫瘤學 |
Hematologic Oncology |
1 |
16 |
陳忠平 |
Zhong-ping Chen |
腫瘤學 |
Oncology |
血管擬態 |
Vascular mimicry |
2 |
17 |
李疆 |
Jiang Li |
腫瘤學 |
Oncology |
腫瘤免疫 |
Cancer Immunology |
1 |
18 |
夏云飛 |
Yunfei Xia |
腫瘤學 |
Oncology |
放射腫瘤學 |
Radiation Oncology |
1 |
19 |
符立梧 |
Liwu Fu |
腫瘤學 |
Oncology |
腫瘤藥理學 |
Cancer Pharmacology |
3 |
20 |
關新元 |
Xin-Yuan Guan |
分子生物學 |
Molecular Biology |
腫瘤微環境和腫瘤發生 |
Microenvironment and tumorigenesis |
1 |
21 |
李 焱 |
Yan Li |
腫瘤學 |
Oncology |
腫瘤發生分子機制 |
Molecular tumorigenesis |
1 |
22 |
劉強 |
Quentin Qiang Liu |
腫瘤學 |
Oncology |
腫瘤分子靶向治療 |
Molecular Target Therapy |
2 |
23 |
徐瑞華 |
Rui-huaXu |
腫瘤學 |
Oncology |
胃腸腫瘤精準治療 |
Precise treatment in gastrointestinal cancer |
5 |
24 |
曾木圣 |
MushengZeng |
腫瘤學/病毒學 |
tumor biology/virology |
EBV感染及EBV疫苗/腫瘤標志及分子顯像/腫瘤免疫機制及免疫治療 |
EBV infection and EBV vaccine/tumor marker and molecular imaging/ Tumor immune mechanism and immunotherapy |
2 |
25 |
高嵩 |
Song Gao |
分子醫學 |
Molecular Medicine |
抗腫瘤藥物靶點的結構解析 |
Structural study of anti-tumor drug targets |
1 |
26 |
孫穎 |
Ying Sun |
腫瘤放射治療學 |
Radiation oncology |
鼻咽癌分子預后與多學科精準治療 |
Molecular prognosis and multidisciplinary precision therapy of nasopharyngeal carcinoma |
2 |
27 |
譚靜 |
Jing Tan |
腫瘤學 |
Oncology |
腫瘤的精準診療 |
4 | |
28 |
劉然義 |
Ran-yi Liu |
腫瘤學 或 分子醫學 |
Oncology or Molecular Medicine |
惡性腫瘤靶向治療 |
Malignant tumor targeting therapy |
2 |
29 |
黃蓬 |
Peng Huang |
腫瘤學,分子醫學,藥學 |
Oncology, molecular medicine, pharmacology |
腫瘤代謝異常的調控機制與藥物干預的研究,抗腫瘤藥物的研發 |
Regulatory mechanisms of metabolic alterations in cancer and pharmacological intervention. Development of novel anticancer agents. |
3 |
30 |
李安華 |
Anhua Li |
超聲醫學 |
Medical Ultrasound |
介入超聲 |
Interventional Ultrasound |
1 |
31 |
錢朝南 |
Chao-Nan Qian |
腫瘤學 |
Oncology |
腫瘤轉移分子機制,或腫瘤血管劫留的分子機制 |
The molecular mechanisms underlying metastasis or vessel co-option in solid tumor |
1 |
32 |
黃文林 |
Wenlin Huang |
腫瘤學 或 分子醫學 |
Oncology or Molecular Medicine |
腫瘤分子生物學 |
Cancer Molecular Biology |
2 |
33 |
鄭利民 |
LiminZheng |
腫瘤學 |
Oncology |
腫瘤免疫 |
Tumor immunology |
1 |
34 |
朱孝峰 |
Xiao-Feng Zhu |
腫瘤學 |
Oncology |
腫瘤信號轉導與靶向藥物 |
Signal transduction and targeted anticancer drug |
1 |
35 |
張力 |
Zhang Li |
腫瘤學 |
Medical Oncology |
1、肺癌及鼻咽癌新藥的臨床前研究;2、肺癌及鼻咽癌分子分型及靶向藥物治療研究 |
1、Studies of preclinical drug treating lung cancer and nasopharyngeal carcinoma; 2、Molecular classification and targeted drug therapy of lung cancer and nasopharyngeal cancer |
2 |
36 |
貝錦新 |
Bei Jin-Xin |
腫瘤學 |
Oncology |
腫瘤遺傳學和基因組學;生物信息學 |
Cancer Genetics and Genomics;Bioinformatics |
2 |
37 |
謝丹 |
Dan Xie |
腫瘤學 |
Oncology |
消化系統腫瘤轉移機制 |
The mechanisms of metastasis in GI tumors |
2 |
38 |
賈衛華 |
Wei-HuaJia |
流行病學/腫瘤學 |
Oncology/Epidemiology |
腫瘤遺傳與基因組學,腫瘤流行病學 |
Cancer genetics and genomes; Cancer epidemiology |
2 |
39 |
周芳堅 |
Fangjian Zhou |
腫瘤學 |
Oncology |
膀胱癌發病機制的研究 |
The mechanism of bladder urothelial carcinoma |
1 |
40 |
張星 |
Xing Zhang |
腫瘤學 |
Oncology |
分子靶向治療和免疫治療 |
New molecular targeted therapy and immunotherapy |
1 |
41 |
張福君 |
Fujun Zhang |
腫瘤學 |
Oncology |
分子影像學;腫瘤微創治療 |
Molecular imaging;Minimally invasive treatment of tumor |
2 |
42 |
鄧務國 |
Wuguo Deng |
腫瘤學 |
Oncology |
腫瘤基因表達調控 |
Tumor gene expression regulation |
2 |
43 |
夏建川 |
JianchuanXia |
免疫治療 |
immunotherapy |
腫瘤免疫治療、腫瘤病因學 |
Tumor immunotherapy、Tumor etiology |
1 |
44 |
麥海強 |
Hai-Qiang Mai |
臨床醫學 |
Clinical medicine |
鼻咽癌 |
Nasopharyngeal carcinoma |
1 |
45 |
買世娟 |
Shi-Juan Mai |
腫瘤學 |
Oncology |
腫瘤轉移標志物 |
Tumor metastasis biomarker |
1 |
46 |
宋立兵 |
Li-Bing Song |
腫瘤學、分子醫學 |
Oncology; Molecular medicine |
腫瘤分子機制及其標記物 |
Molecular Mechanism & Biomarker of Tumor |
1 |
47 |
楊大俊 |
腫瘤學 |
Cancer Biology and target therapy |
靶向藥物個體化治療的轉化研究 |
Anti-cancer drug research and translational research |
2 | |
48 |
曹素梅 |
Su-Mei Cao |
腫瘤流行病學 |
Cancer Epidemiology |
腫瘤流行病學;腫瘤篩查 |
Cancer Epidemiology |
2 |
300多萬優質簡歷
17年行業積淀
2萬多家合作名企業
微信掃一掃 使用小程序